OBJECTIVE: To determine the expression of lipoxygenase (LOX) pathway receptors in ovarian cancer as a potential target for anti-LOX-based therapy. STUDY DESIGN: Paraffin-embedded tumor samples from epithelial ovarian cancer patients were used to construct tissue microarrays to stain for the proposed sites of inhibition of a LOX inhibitor (5-LOX, LTB4-BLT1, and LTB4-BLT2). RESULTS: 245 samples were available for interpretation. Strong expression was demonstrated in 45%, 34%, and 6% of ovarian cancer for LTB4-BLT2, LTB4-BLT1, and 5-LOX, respectively. Expression of LTB4-BLT2 correlated with advanced stage III/IV disease (P = .05), suboptimal debulking (P = .07), and platinum resistance (P = .03). No correlation was seen with regard to disease-free survival. CONCLUSIONS: LOX pathway receptor expression was found in the majority of cancers evaluated. Additionally, LTB4-BLT2 expression portends worse clinical parameters for ovarian cancer. Thus, further investigation on the role of LOX pathway in ovarian cancer is warranted.
OBJECTIVE: To determine the expression of lipoxygenase (LOX) pathway receptors in ovarian cancer as a potential target for anti-LOX-based therapy. STUDY DESIGN:Paraffin-embedded tumor samples from epithelial ovarian cancerpatients were used to construct tissue microarrays to stain for the proposed sites of inhibition of a LOX inhibitor (5-LOX, LTB4-BLT1, and LTB4-BLT2). RESULTS: 245 samples were available for interpretation. Strong expression was demonstrated in 45%, 34%, and 6% of ovarian cancer for LTB4-BLT2, LTB4-BLT1, and 5-LOX, respectively. Expression of LTB4-BLT2 correlated with advanced stage III/IV disease (P = .05), suboptimal debulking (P = .07), and platinum resistance (P = .03). No correlation was seen with regard to disease-free survival. CONCLUSIONS: LOX pathway receptor expression was found in the majority of cancers evaluated. Additionally, LTB4-BLT2 expression portends worse clinical parameters for ovarian cancer. Thus, further investigation on the role of LOX pathway in ovarian cancer is warranted.
Authors: Kristin L White; Joellen M Schildkraut; Rachel T Palmieri; Edwin S Iversen; Andrew Berchuck; Robert A Vierkant; David N Rider; Bridget Charbonneau; Mine S Cicek; Rebecca Sutphen; Michael J Birrer; Paul P D Pharoah; Honglin Song; Jonathan Tyrer; Simon A Gayther; Susan J Ramus; Nicolas Wentzensen; Hannah P Yang; Montserrat Garcia-Closas; Catherine M Phelan; Julie M Cunningham; Brooke L Fridley; Thomas A Sellers; Ellen L Goode Journal: Cancer Res Date: 2012-01-26 Impact factor: 12.701
Authors: Ji Min Seo; Kyung Jin Cho; Eun Young Kim; Man Ho Choi; Bong Chul Chung; Jae Hong Kim Journal: Exp Mol Med Date: 2011-03-31 Impact factor: 8.718
Authors: Colette Galet; Kiran Gollapudi; Sevan Stepanian; Joshua B Byrd; Susanne M Henning; Tristan Grogan; David Elashoff; David Heber; Jonathan Said; Pinchas Cohen; William J Aronson Journal: Cancer Prev Res (Phila) Date: 2013-10-29